The Medicines Company (MDCO)
(Delayed Data from NSDQ)
$31.89 USD
+0.61 (1.95%)
Updated May 3, 2019 04:00 PM ET
After-Market: $31.90 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
0 items in cart
[MDCO]
Reports for Purchase
Showing records 21 - 40 ( 239 total )
Industry: Medical - Biomedical and Genetics
Industry: Medical - Biomedical and Genetics
Industry: Medical - Biomedical and Genetics
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Industry: Medical - Biomedical and Genetics
Industry: Medical - Biomedical and Genetics
Our Proprietary Doc Survey Makes It Clear M-A Interest Is High
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Industry: Medical - Biomedical and Genetics
Industry: Medical - Biomedical and Genetics
ORION-11 Data Puts Inclisiran on Top of M-A Board
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Industry: Medical - Biomedical and Genetics
Industry: Medical - Biomedical and Genetics
Decoding the Press Release Points to a Grand Entrance for ORION-11 at ESC
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Industry: Medical - Biomedical and Genetics
Healthcare - Earnings Recap: The More Analysis, The Merrier, Especially When Data-Driven
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Industry: Medical - Biomedical and Genetics
Industry: Medical - Biomedical and Genetics
With ORION-11 Data Imminent, Let''s Go Digging
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Industry: Medical - Biomedical and Genetics
Industry: Medical - Biomedical and Genetics
Inclisiran Soon To Be Proven An Efficient Frontier
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.